Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/12/2025 | $7.00 | Buy | H.C. Wainwright |
| 3/4/2024 | $7.00 | Buy | H.C. Wainwright |
EFFECT - Connect Biopharma Holdings Ltd (0001835268) (Filer)
S-8 - Connect Biopharma Holdings Ltd (0001835268) (Filer)
F-3 - Connect Biopharma Holdings Ltd (0001835268) (Filer)
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 – SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the presentation of clinical data
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details are as follows: Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001671Presenter: Rekha Chaudhuri, M.D.Sessio
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced that company management will participate in the following upcoming conferences: Noble Capital Markets Virtual Conference Format: Corporate PresentationDate: Wednesday, June 4th, 2025Time: 9:00 a.m. ET Jefferies Healthcare ConferenceFormat: Corporate PresentationDate: Thursday, June 5th, 2025Time: 7:35 a.m. ETWebcast Link: Register Here The live webcast for the Jefferies Healthcare Conference w
H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00
H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00
The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to d
Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings L